65,437 trials
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
Major Depressive Disorder
Primary: SQ Anger/Hostility Scale — 4.8; 8; 6.7; 7.5 Score on Anger/Hostility Scale
Morbid Obesity
Primary: Triglycerides Post-prandial — 95; 71; 134 mmol/L
Rheumatoid Arthritis
Primary: Change From Baseline in Joint Erosion Volume Measured by 3-Dimensional Computed Tomography (3D CT) Scan — 571.4; 369.8; 9.1; -0.4 cubic millimeter (mm^3) — p=0.28
Type 2 Diabetes · Obesity
Primary: The Change in Circulating RAS Activity After Calcitriol/Placebo Therapy — 0; -1.3 ng/mL/h — p=0.69
Attention Deficit Hyperactivity Disorder · Reading Disabilities
Primary: Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention — 1.1; 1.7; 1.0; 1.3 Units on a scale
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Osteoporosis · Bone Diseases, Metabolic
Primary: Guideline Concordant Osteoporosis Therapy — 2537; 2477 Participants
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
Bipolar Disorder
Primary: Percent Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status at 16 Weeks — 10.1053; 3.6364 percentage of change
Smoking
Primary: Maximum Concentration (Cmax) of Nicotine Following Single Use of CHTP 1.1 M and mCC — 6.2950; 9.8463 ng/mL
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Median Time to Paracentesis — 28; 14 days — p=0.17
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute
Primary: Survial Rate at 30 Days — 100; 97 percentage of participants
Small Cell Lung Cancer
Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants
Hemophilia B
Primary: Number of Bleeding Episodes (Annual Bleeding Event Rate) During Periodic Replacement Therapy — 2.00 Bleeding events/year